TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC

NCT ID: NCT05250843

Last Updated: 2023-10-13

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-30
• Study Completion Date: 2024-12-30

Brief Summary

The purpose of the study is to observe the effect of TACE/HAIC combined with lenvatinib and sintilimab as a neoadjuvant therapy before liver resection in preventing the recurrence in high-risk patients with hepatocellular carcinoma.

Detailed Description

For patients with hepatocellular carcinoma staged BCLC B/C(intermediate hepatocellular carcinoma)，TACE is a widely used treatments .However ,The efficacy of TACE in intermediate hepatocellular carcinoma is not very satisfactory.A series of study demonstrated that direct hepatectomy has better prognosis compared with TACE for these intermediate hepatocellular carcinoma patients.Despite of this ,The high recurrence risk, high probability of surgical complications, and poor treatment effect after recurrence of intermediate hepatocellular carcinoma after direct surgical treatment is a still a tough problem to be solved.Recently, investigators have showed that hepatic arterial infusion of FOLFOX-based chemotherapy (HAIC) was safe and efficient for advanced HCC patients. The combination of TACE with HAIC (TACE-HAIC) was proved to increase the local doses of chemotherapeutic agents in the liver .In addition, Lenvatinib was proved non-inferior to sorafenib in overall survival in advanced hepatocellular carcinoma, and Programmed Cell Death Protein-1 (PD-1) antibody was effective and tolerable in patients with advanced hepatocellular carcinoma.In this context，for those patients with potentially high recurrence risk after liver resection, the investigators carried out this prospective randomized control to demonstrate the superiority of TACE/HAIC combined with PD-1 antibody and lenvatinib as a neoadjuvant therapy before liver resection over direct hepatectomy.

Conditions

Hepatocellular Carcinoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TACE/HAIC and Lenvatinib and PD-1(Sintilimab) before liver resection

For patients staged BCLC B/C,TACE/HAIC combined with Lenvatinib and Sintilimab will be conducted as neoadiuvent therapy before liver resection

Group Type: EXPERIMENTAL

TACE/HAIC

Intervention Type: PROCEDURE

Within 1-3 days of lenvatinib and sintilimab, start Transarterial chemobolization treatment or FOLFOX-based chemotherapy infusion,after three months,patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection.

Lenvatinib

Intervention Type: DRUG

Participants received lenvatinib capsules 8mg for patients weight \<60kg, or 12mg for patients weight more than 60Kg.

Sintilimab

Intervention Type: DRUG

Sintilimab Injection will be administered every three weeks (200mg) until surgery or disease progression.

Direct surgery group

After being diagnosed with hepatocellular carcinoma, surgery will be immediately performed.

Group Type: ACTIVE_COMPARATOR

liver resection

Intervention Type: PROCEDURE

liver resection is feasible after evaluation by the liver cancer surgery expert group

Interventions

TACE/HAIC

Within 1-3 days of lenvatinib and sintilimab, start Transarterial chemobolization treatment or FOLFOX-based chemotherapy infusion,after three months,patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection.

Intervention Type: PROCEDURE

Lenvatinib

Participants received lenvatinib capsules 8mg for patients weight \<60kg, or 12mg for patients weight more than 60Kg.

Intervention Type: DRUG

Sintilimab

Sintilimab Injection will be administered every three weeks (200mg) until surgery or disease progression.

Intervention Type: DRUG

liver resection

liver resection is feasible after evaluation by the liver cancer surgery expert group

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• 1) Age 18-70 years old, gender is not limited.
• 2)The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL).
• 3)Patients must have at least one tumor lesion that can be accurately measured.
• 4)Conform to any of the following criteria (1) multiple nodules >3; (2) ≥2 nodules, any of which is >3 cm; (3) invasion of the portal vein or hepatic vein.
• 5)According to the 2022 edition of the Chinese guidelines for the diagnosis and treatment of primary liver cancer, one-stage liver cancer resection is feasible after evaluation by the liver cancer surgery expert group
• 6)No previous anti-HCC treatment.
• 7)Eastern Co-operative Group performance status 2 or less.
• 8)Liver function: Child's A or B (score < 7).

Exclusion Criteria

• 1)Patients with definite tumor thrombus and distant metastasis in the main portal vein and inferior vena cava;
• 2) Allergy to the components of intervention-related drugs such as lipiodol and chemotherapeutic drugs;
• 3) Local treatment (including intervention, surgery, ablation, etc.) and systemic treatment (chemotherapy, targeted drugs and immune checkpoint inhibitors, etc.) for liver cancer within the past 2 months

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

Sponsor Role: lead

Responsible Party

Zhang Yingcai

doctorate

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Third Affiliated Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, China

Site Status: RECRUITING

Countries

China

Facility Contacts

Yang Yang, PHD, MD

Role: primary

yysysu@163.com

020-85252113

Yingcai Zhang, PHD, MD

Role: backup

76207884@qq.com

Other Identifiers

LHuanxian

Identifier Type: -

Identifier Source: org_study_id